產品編號 | bs-4817R-BF350 |
英文名稱1 | Rabbit Anti-CD4/BF350 Conjugated antibody |
中文名稱 | BF350標記的CD4抗體 |
別 名 | CD4 (L3T4); CD4 antigen (p55); CD4 Antigen ; CD4 molecule; CD4 Receptor; CD4+ Lymphocyte deficiency, included; CD4mut; L3T4; Leu3; Ly-4; Lymphocyte antigen CD4; MGC165891; p55; T Cell Antigen T4 ; T cell antigen T4/LEU3; T cell differentiation antigen L3T4; T cell OKT4 deficiency, included; T cell surface antigen T4/Leu 3 ; T cell surface antigen T4/Leu3; T Cell Surface Glycoprotein CD4; W3/25; W3/25 antigen; T-cell surface glycoprotein CD4 isoform 1 precursor; CD4_HUMAN. |
規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
說 明 書 | 100ul |
研究領域 | 腫瘤 細胞生物 免疫學 干細胞 淋巴細胞 t-淋巴細胞 |
抗體來源 | Rabbit |
克隆類型 | Polyclonal |
交叉反應 | Human, |
產品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
分 子 量 | 48kDa |
性 狀 | Lyophilized or Liquid |
濃 度 | 1mg/ml |
免 疫 原 | KLH conjugated synthetic peptide derived from human CD4 |
亞 型 | IgG |
純化方法 | affinity purified by Protein A |
儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
產品介紹 |
background: This gene encodes a membrane glycoprotein of T lymphocytes that interacts with major histocompatibility complex class II antigenes and is also a receptor for the human immunodeficiency virus. This gene is expressed not only in T lymphocytes, but also in B cells, macrophages, and granulocytes. It is also expressed in specific regions of the brain. The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcript variants encoding different isoforms have been identified in this gene. [provided by RefSeq, Aug 2010]. Function: Accessory protein for MHC class-II antigen/T-cell receptor interaction. May regulate T-cell activation. Induces the aggregation of lipid rafts. Subunit: Associates with LCK. Binds to HIV-1 gp120 and to P4HB/PDI and upon HIV-1 binding to the cell membrane, is part of P4HB/PDI-CD4-CXCR4-gp120 complex. Interacts with HIV-1 Envelope polyprotein gp160 and protein Vpu. Interacts with Human Herpes virus 7 capsid proteins. Interacts with PTK2/FAK1; this interaction requires the presence of HIV-1 gp120. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Note=Localizes to lipid rafts. Removed from plasma membrane by HIV-1 Nef protein that increases clathrin-dependent endocytosis of this antigen to target it to lysosomal degradation. Cell surface expression is also down-modulated by HIV-1 Envelope polyprotein gp160 that interacts with, and sequesters CD4 in the endoplasmic reticulum. Post-translational modifications: Palmitoylation and association with LCK contribute to the enrichment of CD4 in lipid rafts. Similarity: Contains 3 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 Ig-like V-type (immunoglobulin-like) domain. Database links: Entrez Gene: 920 Human Entrez Gene: 12504 Mouse Omim: 186940 Human SwissProt: P06332 Mouse SwissProt: P01730 Human Unigene: 631659 Human Unigene: 2209 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. CD4分子是存在于大多數(shù)輔助/誘導T細胞表面的59kDa的糖蛋白。正常淋巴組織中CD4的表達數(shù)量多于CD8,此抗體主要用于標記輔助/誘導T細胞,與CD8單抗聯(lián)合使用對外周血淋巴細胞分型。 CD4抗原是HLA-II類分子和人類免疫缺陷病毒(HIV)-愛滋病的受體,在35-50%外周血淋巴細胞-輔助和誘導T細胞(Th/Ti)和70-80%人胸腺細胞上表達,在人的單核細胞表面也有低密度的表達。 CD4抗原有膜結合型和可溶性兩種形式。Th/Ti可輔助Ig產生和T細胞毒T細胞的作用。 |
1、抗體溶解方法 | |
2、抗體修復方式 | |
3、常用試劑的配制 | |
4、免疫組化操作步驟 | |
5、免疫組化問題解答 | |
6、Western Blotting 操作步驟 | |
7、Western Blotting 問題解答 | |
8、關于肽鏈的設計 | |
9、多肽的溶解與保存 | |
10、酶標抗體效價測定程序 | |